BRIEF-Elicio Therapeutics Reports Results From Phase 2 AMPLIFY-7P Study And Outlines Refined Phase 3 Development Strategy For ELI-002 7P In Adjuvant Pancreatic Cancer

Elicio Therapeutics, Inc

Elicio Therapeutics, Inc

ELTX

0.00

June 15 (Reuters) - Elicio Therapeutics Inc ELTX.O:

  • ELICIO THERAPEUTICS REPORTS RESULTS FROM PHASE 2 AMPLIFY-7P STUDY AND OUTLINES REFINED PHASE 3 DEVELOPMENT STRATEGY FOR ELI-002 7P IN ADJUVANT PANCREATIC CANCER

  • ELICIO THERAPEUTICS - AMPLIFY-7P PHASE 2 STUDY DOES NOT MEET PRIMARY DFS ENDPOINT IN INTENT-TO-TREAT POPULATION

  • ELICIO THERAPEUTICS - ELI-2 7P DEMONSTRATES FAVORABLE SAFETY AND TOLERABILITY PROFILE

  • ELICIO THERAPEUTICS - EVALUATING STRATEGIC FINANCING AND PARTNERING OPPORTUNITIES

  • ELICIO THERAPEUTICS - TO FOCUS PHASE 3 DEVELOPMENT ON R0 RESECTED POPULATION WITH ADDITIONAL ELI-2 7P DOSING

Source text: ID:nGNXbVchpw

Further company coverage: ELTX.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.